Abivax (ABVX) Free Cash Flow (2024 - 2026)

Abivax's Free Cash Flow history runs 3 years deep, the most recent figure standing at $63220.3 for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 100.18% year-over-year to $63220.3 in Q1 2026; TTM through Mar 2026 was -$148.2 million, a 9.97% increase from a year earlier, with the FY2025 full-year figure at -$187.7 million, down 12.07% from the prior year.
• Free Cash Flow rose to $63220.3 in Q1 2026 per ABVX's latest filing, from -$27.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $63220.3 in Q1 2026 and bottomed at -$83.3 million in Q3 2025.
• The 3-year median for Free Cash Flow is -$37.7 million (2025), against an average of -$39.0 million.
• Across the five-year window, Free Cash Flow sank 116.38% in 2025 and soared 100.18% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$37.1 million in 2024, then rose by 26.62% to -$27.2 million in 2025, then soared by 100.23% to $63220.3 in 2026.
• Per Business Quant, the three latest ABVX Free Cash Flow figures stand at $63220.3 (Q1 2026), -$27.2 million (Q4 2025), and -$83.3 million (Q3 2025).